BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 30687303)

  • 1. Genome-Based Approach Delivers Vaccine Candidates Against
    Bianconi I; Alcalá-Franco B; Scarselli M; Dalsass M; Buccato S; Colaprico A; Marchi S; Masignani V; Bragonzi A
    Front Immunol; 2018; 9():3021. PubMed ID: 30687303
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Construction of a Protective Vaccine Against Lipopolysaccharide-Heterologous
    Liu C; Pan X; Xia B; Chen F; Jin Y; Bai F; Priebe G; Cheng Z; Jin S; Wu W
    Front Immunol; 2018; 9():1737. PubMed ID: 30093906
    [No Abstract]   [Full Text] [Related]  

  • 3. Construction of Genomic Library and High-Throughput Screening of Pseudomonas aeruginosa Novel Antigens for Potential Vaccines.
    Xu W; Li L; Wen X; Liu Q; Liu Y; Wang X; Lei L; Chen Q; Liu L
    Biol Pharm Bull; 2020 Oct; 43(10):1469-1475. PubMed ID: 32779581
    [TBL] [Abstract][Full Text] [Related]  

  • 4. IL-17 is a critical component of vaccine-induced protection against lung infection by lipopolysaccharide-heterologous strains of Pseudomonas aeruginosa.
    Priebe GP; Walsh RL; Cederroth TA; Kamei A; Coutinho-Sledge YS; Goldberg JB; Pier GB
    J Immunol; 2008 Oct; 181(7):4965-75. PubMed ID: 18802100
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intranasal Peptide-Based FpvA-KLH Conjugate Vaccine Protects Mice From
    Sen-Kilic E; Blackwood CB; Boehm DT; Witt WT; Malkowski AC; Bevere JR; Wong TY; Hall JM; Bradford SD; Varney ME; Damron FH; Barbier M
    Front Immunol; 2019; 10():2497. PubMed ID: 31708925
    [No Abstract]   [Full Text] [Related]  

  • 6. Mucosal vaccination with a multivalent, live-attenuated vaccine induces multifactorial immunity against Pseudomonas aeruginosa acute lung infection.
    Kamei A; Coutinho-Sledge YS; Goldberg JB; Priebe GP; Pier GB
    Infect Immun; 2011 Mar; 79(3):1289-99. PubMed ID: 21149583
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum albumin nanoparticles vaccine provides protection against a lethal Pseudomonas aeruginosa challenge.
    Maria de Souza Morais S; Ferreira Rodigues N; Ingrid Oliveira da Silva N; Aparecido Salvador E; Rodrigues Franco I; Augusto Pires de Souza G; Henrique Cruvinel da Silva P; Gustavo Nogueira de Almeida L; Prado Rocha R; Carolina Toledo da Cunha Pereira A; Portela Ferreira G; Veras Quelemes P; Pereira de Araújo M; Fornias Sperandio F; Júnia de Souza Santos L; Assis Martins Filho O; Cosme Cotta Malaquias L; Felipe Leomil Coelho L
    Vaccine; 2018 Oct; 36(43):6408-6415. PubMed ID: 30228029
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vaccination against respiratory Pseudomonas aeruginosa infection.
    Grimwood K; Kyd JM; Owen SJ; Massa HM; Cripps AW
    Hum Vaccin Immunother; 2015; 11(1):14-20. PubMed ID: 25483510
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Salmonella Typhimurium strain expressing OprF-OprI protects mice against fatal infection by Pseudomonas aeruginosa.
    Zhang M; Sun C; Gu J; Yan X; Wang B; Cui Z; Sun X; Tong C; Feng X; Lei L; Han W
    Microbiol Immunol; 2015 Sep; 59(9):533-44. PubMed ID: 26249788
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The protective effects of nasal PcrV-CpG oligonucleotide vaccination against Pseudomonas aeruginosa pneumonia.
    Naito Y; Hamaoka S; Kinoshita M; Kainuma A; Shimizu M; Katoh H; Moriyama K; Ishii KJ; Sawa T
    Microbiol Immunol; 2018 Dec; 62(12):774-785. PubMed ID: 30378708
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Killed but metabolically active Pseudomonas aeruginosa-based vaccine induces protective humoral- and cell-mediated immunity against Pseudomonas aeruginosa pulmonary infections.
    Meynet E; Laurin D; Lenormand JL; Camara B; Toussaint B; Le Gouëllec A
    Vaccine; 2018 Mar; 36(14):1893-1900. PubMed ID: 29506924
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunization with outer membrane proteins (OprF and OprI) and flagellin B protects mice from pulmonary infection with mucoid and nonmucoid Pseudomonas aeruginosa.
    Hassan R; El-Naggar W; Abd El-Aziz AM; Shaaban M; Kenawy HI; Ali YM
    J Microbiol Immunol Infect; 2018 Jun; 51(3):312-320. PubMed ID: 28291719
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prediction of vaccine candidates against Pseudomonas aeruginosa: An integrated genomics and proteomics approach.
    Rashid MI; Naz A; Ali A; Andleeb S
    Genomics; 2017 Jul; 109(3-4):274-283. PubMed ID: 28487172
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mucosal and systemic antibody responses to potential Pseudomonas aeruginosa vaccine protein antigens in young children with cystic fibrosis following colonization and infection.
    Moore R; Kyd JM; Carzino R; Armstrong D; Grimwood K; Otczyk DC; Cripps AW
    Hum Vaccin Immunother; 2013 Mar; 9(3):506-14. PubMed ID: 23249482
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recent developments for Pseudomonas vaccines.
    Sharma A; Krause A; Worgall S
    Hum Vaccin; 2011 Oct; 7(10):999-1011. PubMed ID: 21941090
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of a conjugate vaccine containing polymannuronic acid and flagellin against experimental Pseudomonas aeruginosa lung infection in mice.
    Campodónico VL; Llosa NJ; Bentancor LV; Maira-Litran T; Pier GB
    Infect Immun; 2011 Aug; 79(8):3455-64. PubMed ID: 21628521
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rational Design of a Chimeric Derivative of PcrV as a Subunit Vaccine Against
    Wan C; Zhang J; Zhao L; Cheng X; Gao C; Wang Y; Xu W; Zou Q; Gu J
    Front Immunol; 2019; 10():781. PubMed ID: 31068928
    [No Abstract]   [Full Text] [Related]  

  • 18. Immunological evaluation of an alginate-based conjugate as a vaccine candidate against Pseudomonas aeruginosa.
    Farjah A; Owlia P; Siadat SD; Mousavi SF; Ardestani MS; Mohammadpour HK
    APMIS; 2015 Feb; 123(2):175-83. PubMed ID: 25470757
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy comparison of adjuvants in PcrV vaccine against Pseudomonas aeruginosa pneumonia.
    Hamaoka S; Naito Y; Katoh H; Shimizu M; Kinoshita M; Akiyama K; Kainuma A; Moriyama K; Ishii KJ; Sawa T
    Microbiol Immunol; 2017 Feb; 61(2):64-74. PubMed ID: 28370521
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Th17-stimulating protein vaccines confer protection against Pseudomonas aeruginosa pneumonia.
    Wu W; Huang J; Duan B; Traficante DC; Hong H; Risech M; Lory S; Priebe GP
    Am J Respir Crit Care Med; 2012 Sep; 186(5):420-7. PubMed ID: 22723292
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.